Morphoproteomics and biomedical analytics coincide with clinical outcomes in supporting a constant but variable role for the mTOR pathway in the biology of congenital hyperinsulinism of infancy

We first introduced the concept of the mTOR pathway’s involvement in congenital hyperinsulinism of infancy (CHI), based largely on morphoproteomic observations and clinical outcomes using sirolimus (rapamycin) as a therapeutic agent in infants refractory to octreotide and diazoxide treatment. Subseq...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Robert E., Senniappan, Senthil, Hussain, Khalid, McGuire, Mary F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732475/
https://www.ncbi.nlm.nih.gov/pubmed/29246172
http://dx.doi.org/10.1186/s13023-017-0735-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732475/
https://www.ncbi.nlm.nih.gov/pubmed/29246172
http://dx.doi.org/10.1186/s13023-017-0735-9

Ejemplares similares